Last reviewed · How we verify

Placebo to DOR

Merck Sharp & Dohme LLC · Phase 3 active Small molecule

DOR is a delta opioid receptor agonist that activates delta opioid receptors to modulate pain signaling and potentially provide analgesic effects.

DOR is a delta opioid receptor agonist that activates delta opioid receptors to modulate pain signaling and potentially provide analgesic effects. Used for Chronic pain (investigational).

At a glance

Generic namePlacebo to DOR
SponsorMerck Sharp & Dohme LLC
Drug classDelta opioid receptor agonist
TargetDOR (Delta opioid receptor)
ModalitySmall molecule
Therapeutic areaPain Management
PhasePhase 3

Mechanism of action

Delta opioid receptors (DOR) are G-protein coupled receptors involved in pain modulation, mood regulation, and neuroprotection. Agonism at these receptors can produce analgesia through spinal and supraspinal mechanisms while potentially offering a different safety and abuse liability profile compared to mu opioid receptor agonists. This mechanism may provide pain relief with reduced respiratory depression and addiction potential.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: